Want to see HK:2575 full AI Analyst Report?
2575 Stock Chart & Stats
HK$12.95
--
Market closed
HK$12.95
--
Day’s Range― - ―
52-Week RangeHK$10.60 - HK$96.90
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
HK$5.73B
Enterprise ValueHK$35.75K
Total Cash (Recent Filing)HK$216.62M
Total Debt (Recent Filing)HK$1.37M
Price to Earnings (P/E)―
Beta2.38
Next Earnings
Aug 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding517,947,800
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio2.47
Price to Book (P/B)23.93
Price to Sales (P/S)650.34
P/FCF Ratio-163.31
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Revenue ScalingRapid revenue expansion indicates meaningful commercial progress and growing product adoption. Sustained scaling could improve operating leverage over time, provided the company can convert increased sales into durable profitability.
Improving Gross MarginThe move to positive gross margin is an important operating improvement, suggesting better economics at the product level. Continued margin gains could support a path toward breakeven as revenue scales.
Low Financial LeverageConservative financing reduces interest and refinancing pressure while preserving flexibility to fund development and commercialization. A stronger asset and equity base provides additional runway, although returns remain unproven.
Bears Say
Persistent Operating LossesPersistent operating and net losses show that the business has not yet reached sustainable scale. Until revenue growth produces positive operating leverage, execution remains dependent on further cost control and successful commercialization.
Negative Cash GenerationRecurring negative operating and free cash flow indicates that growth currently consumes capital rather than funding itself. Continued reliance on external funding increases execution risk and could constrain investment if financing conditions weaken.
Negative Returns On CapitalNegative return on equity means the company is not yet generating shareholder value from its capital base. This limits the quality of balance-sheet strength and places greater importance on achieving profitable growth.
Xuanzhu Biopharmaceutical Co., Ltd. Class H News
2575 FAQ
What was Xuanzhu Biopharmaceutical Co., Ltd. Class H’s price range in the past 12 months?
Xuanzhu Biopharmaceutical Co., Ltd. Class H lowest stock price was HK$10.60 and its highest was HK$96.90 in the past 12 months.
What is Xuanzhu Biopharmaceutical Co., Ltd. Class H’s market cap?
Xuanzhu Biopharmaceutical Co., Ltd. Class H’s market cap is HK$5.73B.
When is Xuanzhu Biopharmaceutical Co., Ltd. Class H’s upcoming earnings report date?
Xuanzhu Biopharmaceutical Co., Ltd. Class H’s upcoming earnings report date is Aug 26, 2026 which is in 3 days.
How were Xuanzhu Biopharmaceutical Co., Ltd. Class H’s earnings last quarter?
Xuanzhu Biopharmaceutical Co., Ltd. Class H released its earnings results on Mar 30, 2026. The company reported -HK$0.284 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Xuanzhu Biopharmaceutical Co., Ltd. Class H overvalued?
According to Wall Street analysts Xuanzhu Biopharmaceutical Co., Ltd. Class H’s price is currently Overvalued.
Does Xuanzhu Biopharmaceutical Co., Ltd. Class H pay dividends?
Xuanzhu Biopharmaceutical Co., Ltd. Class H does not currently pay dividends.
What is Xuanzhu Biopharmaceutical Co., Ltd. Class H’s EPS estimate?
Xuanzhu Biopharmaceutical Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Xuanzhu Biopharmaceutical Co., Ltd. Class H have?
Xuanzhu Biopharmaceutical Co., Ltd. Class H has 517,947,800 shares outstanding.
What happened to Xuanzhu Biopharmaceutical Co., Ltd. Class H’s price movement after its last earnings report?
Xuanzhu Biopharmaceutical Co., Ltd. Class H reported an EPS of -HK$0.284 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -8.49%.
Which hedge fund is a major shareholder of Xuanzhu Biopharmaceutical Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2575
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Xuanzhu Biopharmaceutical Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
43.47%
Trailing 12-Months
Company Description
Xuanzhu Biopharmaceutical Co., Ltd. Class H
Xuanzhu Biopharmaceutical Co., Ltd. is a Chinese enterprise dedicated to the research, production, and commercialization of both small-molecule chemical compounds and large-molecule biopharmaceuticals. The company's primary drug candidates include Core- KBP-3571, developed for treating duodenal ulcers; XZP-3287, a CDK4/6 inhibitor aimed at advanced HR+/HER2 breast cancer; and XZP-3621, intended as a first-line therapy for patients suffering from anaplastic lymphoma kinase-positive (ALK+) advanced non-small-cell lung cancer. Its development pipeline further encompasses KM501, a pioneering HER2/HER2 bispecific antibody drug conjugate currently in Phase I clinical trials, alongside KM602, another anti-tumor agent also undergoing Phase I evaluation. Other investigational assets include XZP-7797, a selective and brain-penetrating poly ADP-ribose polymerase 1 (PARP1) inhibitor; XZP-6924, which targets ubiquitin-specific protease 1 (USP1); XZB-0004, an oral small molecule anexelekto inhibitor; and XZP-6877, a DNA-dependent protein kinase inhibitor. The portfolio also features NG-350A, a next-generation oncolytic viral therapy; XZP-5610, a non-steroidal farnesoid X receptor; and XZP-6019, a first-in-class ketohexokinase (KHK) inhibitor. Founded in 2008 and headquartered in Beijing, China, Xuanzhu Biopharmaceutical Co., Ltd. operates as a subsidiary of Sihuan Pharm.
Technical Analysis
HUTCHMED (China)
―
Hua Medicine
―
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
―
Hansoh Pharmaceutical Group Company Limited
―
CanSino Biologics, Inc. Class H
―